The arrival of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable interest within the healthcare community. This novel dual GIP and GLP-1 target medication suggests to offer significant improvements in weight reduction compared to previous therapies. Preliminary patient trials have demonstrated marked reductions in body mass , conceiv